Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction
Authors: Roger Peverill
Journal: Annals of Internal Medicine (2001)

Letters2 January 2001Hormone Therapy and Risk for Venous Thromboembolism: Comments and CorrectionRoger Peverill, MB, BS, PhDRoger Peverill, MB, BS, PhDMonash Medical Centre and Monash University; Clayton 3168, Australia (Peverill)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-1-200101020-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Grady and colleagues (1) speculate that effects of oral estrogen on factor VII and protein C may be possible mechanisms for the prothrombotic effects of hormone replacement therapy (HRT) observed in the Heart and Estrogen/progestin Replacement Study (HERS). I am concerned that the specific points made by the authors about protein C and factor VII provide an oversimplistic and somewhat inaccurate interpretation of the available data.First, Grady and colleagues postulated that the higher levels of protein C seen with the use of estrogen may be thrombogenic. However, protein C is a natural anticoagulant; it is actually ...References1. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al . Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-96. LinkGoogle Scholar2. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al . Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1993;328:1069-75. CrossrefMedlineGoogle Scholar3. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol. 1994;84:987-95. MedlineGoogle Scholar4. Nozaki M, Ogata R, Koera K, Hashimoto K, Nakano H. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric. 1999;2:124-30. CrossrefMedlineGoogle Scholar5. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, et al . Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol. 2000;20:1404-9. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Monash Medical Centre and Monash University; Clayton 3168, Australia (Peverill) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPostmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study Deborah Grady , Nanette K. Wenger , David Herrington , Steven Khan , Curt Furberg , Donald Hunninghake , Eric Vittinghoff , Stephen Hulley , and Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction H. Joan Waitkevicz and Deborah Axelrod Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction Mark R. Goldstein Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction Deborah Grady and Eric Vittinghoff Metrics Cited ByPharmacogenetics 2 January 2001Volume 134, Issue 1Page: 80KeywordsEstrogen replacement therapyEstrogensFibrinHeartHormone replacement therapyLongitudinal studiesProteinsThrombinThrombosisVenous thromboembolism ePublished: 2 January 2001 Issue Published: 2 January 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...